IP Library › Granted Patent US 10,500,245
Granted Patent B2
US 10,500,245 · App. 15/119,032 · Granted Dec 10, 2019

Compositions for preventing and/or treating pathological conditions associated with alpha-glucosidase

Inventors: Thierry Maugard (La Jarne, FR); Stephanie Bordenave-Juchereau (Le Thou, FR); Jean-Marie Piot (Perigny, FR); Yesmine Ben-Henda (La Rochelle, FR); Pascal Sirvent (Ceyrat, FR); Sebastien Peltier (Fouras, FR)
Assignees: UNIVERSITE DE LA ROCHELLE; UNIVERSITE CLERMONT AUVERGNE
A61K38/06A23L33/18A23L33/30A61K38/005A61K38/01A61K38/05A61K45/06A61P3/10A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,500,245
App. No.
15/119,032
Granted
Dec 10, 2019
Kind
B2
Abstract

A composition including at least one XAP peptide, in which X represents the empty set or a valine, for use in the prevention and/or treatment of pathologies associated with alpha-glucosidase. Also, the use of a hydrolysate of at least one protein, the protein including or constituted by at least 0.05% to <5% or of at least 5% of XAP units, in which X represents the empty set or a valine, for use in the prevention and/or treatment of pathologies associated with alpha-glucosidase.

Claims (10)

1. A method for reducing glycemia by inhibiting alpha-glucosidase, said method comprising administering to a subject in need thereof a composition comprising at least one XAP peptide, in which X represents the empty set or a valine, wherein the XAP peptide is administered before or during a meal.

2. The method according to claim 1 , wherein said composition comprises at least one VAP peptide and/or at least one AP peptide in combination with a peptide APX′;

wherein A is alanine, P is proline, and X′ is an amino acid or a group of amino acids selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.

3. The method according to claim 1 , wherein said composition is in unit form and comprises a quantity of XAP peptide from 5 mg to 3000 mg.

4. The method according to claim 1 , wherein said composition comprises a quantity of VAP peptide from 5 mg to 3000 mg, or a quantity of AP peptide from 5 mg to 3000 mg, or a quantity of VAP and AP peptides from 5 mg to 3000 mg.

5. The method according to claim 4 ,

wherein said composition comprises:

a quantity of VAP peptide that is in a range selected from the group consisting of: from 5 mg to 7.4 mg, and from 7.5 mg to 3000 mg; or

a quantity of AP peptide that is in a range selected from the group consisting of: from 5 mg to 7.4 mg, and from 7.5 mg to 3000 mg; or

a quantity of VAP and AP peptides that is in a range selected from the group consisting of: from 5 mg to 7.4 mg, and from 7.5 mg to 3000 mg.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Oct 22, 2019
From: UNIVERSITE BLAISE PASCAL-CLERMONT II; UNIVERSITE CLERMONT AUVERGNE
To: UNIVERSITE CLERMONT AUVERGNE
Reel/Frame 050792/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2017
From: MAUGARD, THIERRY; BORDENAVE-JUCHEREAU, STEPHANIE; PIOT, JEAN-MARIE; BEN-HENDA, YESMINE; SIRVENT, PASCAL; PELTIER, SEBASTIEN
To: UNIVERSITE DE LA ROCHELLE; UNIVERSITE BLAISE PASCAL-CLERMONT II
Reel/Frame 042735/0137 →
Priority Claims (1)
FR 14 51280 · Feb 18, 2014 · national
Continuity (1)
Related Publication 20180104303A1 · Apr 19, 2018